NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Regen BioPharma, Inc. (“Regen” or the “Company”) (OTCMKTS: RGBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (RVNC) – Get Revance Therapeutics, Inc. Report and certain of Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of IronNet, Inc. (“IronNet” or the “Company”) (IRNT) . Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of TPI Composites, Inc. (“TPI” or the “Company”) (TPIC) – Get TPI Composites, Inc. Report. Such investors are advised to contact Robert Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Owlet, Inc. (“Owlet” or the “Company”) f/k/a Sandbridge Acquisition Corporation (“Sandbridge”) (NYSE: OWLT; OWLT WS; SBG) and certain Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Redwire Corporation f/k/a Genesis Park Acquisition Corp. (“Redwire” or the “Company”) (NYSE: RDW). Such investors are advised to contact Robert S. Willoughby Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Sleep Number Corporation f/k/a Select Comfort Corporation (“Sleep Number” or the “Company”) (NASDAQ: SNBR). Such investors are advised to contact Robert S. Willoughby Read more…
SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Zhangmen Education Inc. (“Zhangmen” or the “Company”) (NYSE: ZME). Such investors are advised to contact Robert S. Willoughby at [email protected] or Read more…